Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference8 articles.
1. Atezolizumab versus Docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017
2. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC;Socinski;N Engl J Med,2018
3. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a Multicentre, Randomised, Open-label, phase 3 Trial;West;Lancet Oncol,2019
4. Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors;Ibraheim;Rheumatology,2019
5. Managing immune checkpoint-blocking antibody side effects;Postow;Am Soc Clin Oncol Educ Book,2015
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Safety of immune checkpoint inhibitors: An updated comprehensive disproportionality analysis and meta-analysis;Critical Reviews in Oncology/Hematology;2024-08
2. Immune Checkpoint Inhibitor-induced Sclerosing Cholangitis: Three Cases Reported from Our Hospital;Haigan;2024-06-20
3. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU;Gastroenterología y Hepatología;2024-04
4. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU;Gastroenterología y Hepatología (English Edition);2024-04
5. Atezolizumab‐related sclerosing cholangitis with multiple liver abscesses in a patient with lung squamous cell carcinoma: A case report;Respirology Case Reports;2024-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3